16 results on '"Girgis, Ihab G."'
Search Results
2. First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
3. Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects
4. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
5. Graphical Data Exploration in QT Model Building and Cardiovascular Drug Safety
6. Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants
7. Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants
8. The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants
9. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab
10. Immune Checkpoint Inhibition in Sepsis
11. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
12. Selective Inhibition of Tyrosine Kinase 2 (TYK2) with BMS-986165 Is Efficacious in IL-23-Mediated Diseases: Evidence from Preclinical IBD Models and From a Psoriasis Study
13. The source of hERG IC50 values (manual vs. automated patch clamp) may influence in silico modeling
14. Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age
15. Population Pharmacodynamic Parameter Estimation from Sparse Sampling: Effect of Sigmoidicity on Parameter Estimates
16. Pharmacodynamic parameter estimation: Population size versus number of samples
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.